GlassScriptPhysician profile
Neerja K Sethi
NPI 1649390709
$5,583.37
in general payments reported to CMS, 2019-2025
43 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.98 · 2022: $1,248 · 2023: $1,053 · 2024: $1,393 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,098.79 | 2022-2025 | |
| Novo Nordisk INC | $619.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $593.19 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $479.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $391.97 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $282.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $170.86 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $144.62 | 2022-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amgen INC. | $142.83 | 2022-2025 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $140.06 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $139.12 | 2022-2023 | |
| Abbott Laboratories | $123.96 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.64 | 2022-2023 | |
| Corcept Therapeutics | $103.68 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $102.61 | 2022-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neerja Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.